Browse Studies — Arctuva

Phase 1

Phase 1/Phase 2 Open Label Trial of a Novel Indenoisoquinolone C-MYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma

Background: Glioblastoma is a common brain cancer in adults. Treatment includes surgery, radiation, and chemotherapy. But this cancer can return after treatme…

Recurrent GlioblastomaGlioblastoma IDH (Isocitrate Dehydrogenase) WildtypeRelapsed Cancer+12 more

Estimated

~$10 – $5,625

National Institute of Neurological Disorders and Stroke (NINDS)NCT07416188

Phase 1

Phase 1/2 Trial of Mirdametinib in Patients With MAPK Pathway Mutant Central Nervous System Tumors

The purpose of this study to find out whether mirdametinib is a safe and effective treatment for Central Nervous System/CNS tumors (glioma and neurohistiocytos…

Central Nervous System TumorsGlioma

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT07539441

Genomes for Kids (G4K)

The development of next generation sequencing (NGS) techniques, including whole genome (WGS), exome (WES) and RNA sequencing has revolutionized the ability of …

Solid, Liquid, Central Nervous System Tumors

Estimated

~$10 – $750

St. Jude Children's Research HospitalNCT02530658

Phase 1

A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Central Nervous System Tumors

The purpose of this research study is to learn about the safety and feasibility of giving a personalized DNA vaccine to people with central nervous system tumo…

Pediatric Recurrent Central Nervous System Tumors

Estimated

~$10 – $6,250

Washington University School of MedicineNCT03988283